Thrombotic Thrombocytopenic Purpura (TTP) Market Size
The global thrombotic thrombocytopenic purpura (TTP) market reached USD 1.0 billion in 2022 and is expected to witness lucrative growth by reaching up to USD 1.4 billion by 2031. The global thrombotic thrombocytopenic purpura (TTP) market is expected to exhibit a CAGR of 4.7% during the forecast period (2024-2031).
TTP usually emerges unexpectedly and stays for days or weeks, though it can persist for months. TTP can even push red blood cells to shatter separated quickly than the normal body can substitute them. This directs to an infrequent condition of anemia called hemolytic anemia. TTP can be deadly. Without therapy, it can induce long-term issues, like brain injury or a stroke.
The increase in the number of cases, increasing market developments, rising clinical research activities, and increasing research investments are among other factors expected to boost the global thrombotic thrombocytopenic purpura market growth in the forecast period.
Market Scope
| Metrics | Details |
| CAGR | 4.7% |
| Size Available for Years | 2023-2031 |
| Forecast Period | 2024-2031 |
| Data Availability | Value (US$) |
| Segments Covered | Type, Treatment, End User, and Region |
| Regions Covered | North America, Europe, Asia-Pacific, South America, and Middle East & Africa |
| Fastest Growing Region | Asia-Pacific |
| Largest Region | North America |
| Report Insights Covered | Competitive Landscape Analysis, Company Profile Analysis, Market Size, Share, Growth, Demand, Recent Developments, Mergers and Acquisitions, New Type Launches, Growth Strategies, Revenue Analysis, Porter’s Analysis, Pricing Analysis, Regulatory Analysis, Supply-Chain Analysis, and Other key Insights. |
For More Insights Download Sample
Market Dynamics
Increasing Market Developments Drive The Growth Of The Thrombotic Thrombocytopenic Purpura (TTP) Market
The increasing market developments such as product authorizations, mergers, and acquisitions among others are expected to boost the global thrombotic thrombocytopenic purpura (TTP) market growth in the forecast period. For instance, in May 2023, Takeda Pharmaceutical Company Limited, a Japanese global pharmaceutical corporation obtained the U.S. Food and Drug Administration (FDA) acceptance of Takeda’s Biologics License Application (BLA) for TAK-755, an enzyme replacement treatment indicated for congenital thrombotic thrombocytopenic purpura (cTTP), an ADAMTS13 deficit condition. The TAK-755 application was received by the FDA on May 16, 2023, and has been given a Priority Review.
FDA has even presented TAK-755 Rare Pediatric Disease (RPD) title for cTTP. TAK-755 has formerly obtained Fast Track Designation and Orphan Drug Designation in cTTP. If authorized, TAK-755 is expected to be the foremost and exclusive recombinant ADAMTS13 (rADAMTS13) substitute treatment for cTTP, a condition with significant unmet patient needs.
The Increase Awareness is Expected To Present The Global Thrombotic Thrombocytopenic Purpura (TTP) Market With Growth Opportunities.
The increasing awareness about thrombotic thrombocytopenic purpura (TTP) is expected to present the global market with prospective growth opportunities. For instance, for several years, the Answering T.T.P. Foundation conducted an International TTP Day in September to increase awareness of this rare condition. Funding is gathered for research, but awareness is also concentrated on the tales of those impacted or their family partners, integrated with training activities and the delivery of information materials. The Answering T.T.P. Foundation was set up in 2009 by Sydney Kodatsky, who had TTP herself.
The High Cost Of The Thrombotic Thrombocytopenic Purpura (TTP) Treatment is Estimated To Hamper The Global Thrombotic Thrombocytopenic Purpura (TTP) Market During The Forecast Period.
The high cost of the thrombotic thrombocytopenic purpura (TTP) treatment makes it difficult for the low-income population to opt for the treatment reducing the market demand and thereby its growth in the forecast period. For instance, according to an article published in August 2021, by the American Journal of Managed Care, for plasma exchange or rituximab or caplacizumab, per treatment cost is approximately USD 7,000. Specifically for plasma exchange and caplacizumab, the patient requires to take them daily at least a dose for 1 course.
Market Segment Analysis
The global thrombotic thrombocytopenic purpura (TPP) market is segmented based on type, treatment, end-user, and region.
The Rituximab Treatment is Estimated to Dominate the Global Thrombotic Thrombocytopenic Purpura (TTP) Market.
Owing to the increasing acceptance of Rituximab by distinct healthcare controlling authorities for prophylaxis and treatment of thrombotic thrombocytopenic purpura (TTP) the Rituximab treatment segment is estimated to dominate the global market holding about 27.4% of the entire market by 2030. Rituximab is instructed to be public as a standard commissioning therapy choice for acute thrombotic thrombocytopenic purpura (TTP) and elective therapy to avert TTP relapse in adults and children aged 2 years and above within the standards established.
For instance, in August 2022, NHS England carefully examined the proof of Rituximab for the treatment of acute thrombotic thrombocytopenic purpura (TTP) and elective treatment to avert TTP relapse in adults and children aged 2 years and above. The NHS inferred that there is sufficient proof to make the treatment obtainable at this time. Rituximab delivers a prominent function in the therapy course. It is a monoclonal anti-CD20 antibody that attaches to and operates on CD20, a molecule represented on the surface of B lymphocytes that are accountable for assembling antibodies. These binding lower antibody building and homogenizes ADAMTS13 activity levels thereby lowering clot formation in the blood.
Market Geographical Share
North America is estimated to hold Approximately 38.7% of the Market Share by 2030, Owing to The Increasing in Hospital-Associated Infections.
The presence of government and non-government organizations participating in the fight against thrombotic thrombocytopenic purpura to support the patients and spread awareness and education about the condition in the North American region, the region is estimated to dominate the global market holding about 38.7% of the global market by 2030.
For instance, the National Organization for Rare Disorders, Inc.'s (NORD’s) MedicAlert Assistance Program delivers MedicAlert developments and services to suitable people in the rare disease society including TTP. If a person with a rare condition can’t express themselves in an emergency, MedicAlert can be their representative in delivering crucial and potentially life-saving details. The program delivers suitable people with a MedicAlert development and 3-years of membership.
Moreover, the Rare Disease Education Support Program is developed to present rare condition patients and/or their families/caregivers a prospect to partake in educational agendas and discussions that deliver rare disease content. NORD’s program supplies financial aid for enrollment fees.
Market Companies
The major global players in the market include Pfizer Inc, F. Hoffmann-La Roche Ltd, Aspen Holdings, Fresenius Kabi AG, Novartis AG, Teva Pharmaceutical Industries Ltd., Hikma Pharmaceuticals PLC, Takeda Pharmaceutical Company Limited., CSL Limited and Mylan N.V., among others.
COVID-19 Impact on Market
Russia-Ukraine Conflict Analysis
The Russia-Ukraine conflict is thought to hold a minimal influence on the global thrombotic thrombocytopenic purpura (TTP) market, as there is a low incidence of conditions and a lack of primary market players in this region. Though continuing to countenance invasions from Russian armies, Ukrainian clinics are forced by growing numbers of deaths and limited medical aid. There are shortages across all types of medications. Again, the significance of the import and export of fundamental materials are expected to minimally impact the global thrombotic thrombocytopenic purpura (TTP) market growth in the forecast period.
Key Developments
- In June 2023, Takeda Pharmaceuticals Limited delivered encouraging interim outcomes from a multinational pivotal Phase 3 randomized, controlled, open-label, crossover trial assessing the safeness and effectiveness of TAK-755 (recombinant ADAMTS13) substitute treatment for the prophylactic therapy of congenital thrombotic thrombocytopenic purpura (cTTP), and pharmacokinetics (PK) elements of TAK-755, and long-term data on TAK-755 prophylaxis from a Phase 3b continuation study.
Why Purchase the Report?
- To visualize the global thrombotic thrombocytopenic purpura (TTP) market segmentation based on type, treatment, end-user, and region and understand key commercial assets and players.
- Identify commercial opportunities by analyzing trends and co-development.
- Excel data sheet with numerous data points of thrombotic thrombocytopenic purpura (TTP) market-level with all segments.
- PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
- Product mapping available in Excel consisting of key products of all the major players.
The global thrombotic thrombocytopenic purpura (TTP) market report would provide approximately 53 tables, 54 figures, and 195 Pages.
Target Audience 2023
- Manufacturers/ Buyers
- Industry Investors/Investment Bankers
- Research Professionals
- Emerging Companies
